PET staging in lymphoma
Bone Marrow Involvement in Lymphoma — What Your PET Scan Can Tell You
A PET-CT scan can detect lymphoma in the bone marrow — and for Hodgkin lymphoma and diffuse large B-cell lymphoma, it is now reliable enough that a routine biopsy is no longer needed. The answer depends on which lymphoma you have.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed September 2026
- PET has replaced biopsy in some lymphomas — For Hodgkin lymphoma and DLBCL, guidelines now accept PET as sufficient to assess marrow involvement at staging.
- Diffuse uptake is not always lymphoma — A generalised glow across the marrow can reflect reactive changes — infection, anaemia, or G-CSF — not disease.
- Focal uptake is more specific — A discrete hotspot in bone or marrow is more likely to represent lymphoma and affects how the stage is determined.
- Biopsy is still needed in some cases — In indolent lymphomas and when the PET pattern is uncertain, biopsy remains the more reliable way to confirm marrow involvement.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
In Hodgkin lymphoma and diffuse large B-cell lymphoma, PET-CT is now the standard way to assess bone marrow involvement at staging. NCCN and ESMO guidelines recognise PET findings as sufficient in these cancers, making a routine biopsy unnecessary in most cases. In indolent lymphomas such as follicular lymphoma, biopsy usually remains necessary.
CION offers PET-CT in Hyderabad from Rs 10,499 — among the lowest published prices in the city, with no hidden charges. Indicative price, as of September 2026.
Can a PET scan show whether lymphoma has spread to the bone marrow?
For Hodgkin lymphoma and diffuse large B-cell lymphoma (DLBCL), yes. PET-CT is now the primary tool for marrow assessment at staging, and NCCN and ESMO guidelines support using PET findings alone — so most people with these lymphomas do not need a separate bone marrow biopsy.
PET has a scope advantage: it images the entire skeleton in one examination. A bone marrow biopsy samples one small area — usually the back of the pelvis — and can miss patchy disease at other sites.
In indolent lymphomas such as follicular, marginal zone, or small lymphocytic lymphoma, biopsy remains more reliable. These cancers often infiltrate the marrow in a diffuse, low-level way that PET does not reliably detect.
What do the words in your PET-CT report mean?
- Diffuse marrow uptake
- A broad, even increase in metabolic activity across the marrow of multiple bones. Less specific than focal uptake — it appears in lymphoma but also in reactive states such as anaemia, infection, and G-CSF use.
- Focal marrow uptake
- A discrete, localised area of increased activity at a specific site. More specific for lymphoma involvement, and the pattern staging systems use when classifying marrow as positive.
- FDG-avid lymphoma
- A lymphoma type that takes up the PET tracer (fluorodeoxyglucose) strongly and consistently. Hodgkin lymphoma and DLBCL are the main FDG-avid types — PET is most reliable for marrow assessment in these two.
- Discordant marrow involvement
- When biopsy finds lymphoma in the marrow that PET did not detect. In DLBCL, the marrow can contain a lower-grade cell type that is not FDG-avid. It matters because it changes the stage.
- Reactive marrow
- Marrow that is metabolically active for a non-lymphoma reason — recovery after chemotherapy, G-CSF stimulation, or infection. It can look similar to lymphomatous marrow on PET, which is why scan timing and recent treatment history are always relevant context.
PET-CT Partner Centres
PET-CT Scan Centres in Hyderabad
CION offers PET-CT scans through 4 trusted partner PET-CT centres across Hyderabad, so you can choose the one closest to you. Call 18002028726 and we’ll guide you to the earliest available appointment.
PET-CT Centre — Punjagutta
PET-CT Centre — Himayatnagar
PET-CT Centre — Narayanaguda
These are partner diagnostic centres within the CION network. Toll-free booking: 18002028726.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
When is a bone marrow biopsy still needed alongside PET?
- Your lymphoma is an indolent type such as follicular, marginal zone, or small lymphocytic lymphoma
- PET shows only diffuse uptake with no focal lesions, and the clinical picture remains uncertain
- Your haemato-oncologist needs to check whether a second, lower-grade lymphoma component is present in the marrow
- A clinical trial protocol requires histological confirmation of marrow status
- The treatment decision turns on confirmed marrow involvement, and PET alone is not conclusive for your lymphoma type
What is the difference between diffuse and focal marrow uptake?
| Diffuse uptake | Focal uptake | |
|---|---|---|
| Pattern on scan | Even increase across multiple bones | Discrete hotspot at one or more specific sites |
| Specificity for lymphoma | Lower — also seen in reactive states | Higher — less often caused by non-lymphoma conditions |
| Common non-lymphoma causes | G-CSF, anaemia, infection, post-chemo recovery | Less commonly from non-lymphoma causes |
| Effect on staging | Not always classified as marrow-positive without supporting evidence | Often classified as marrow-positive |
| Typical next step | Clinical correlation; sometimes biopsy | Discussion of stage and treatment with your haemato-oncologist |
Questions about PET findings and marrow involvement
Will marrow involvement change my treatment?
It depends on your lymphoma type. In Hodgkin lymphoma, marrow involvement changes the stage to IV but does not remove the possibility of curative treatment — the prognostic score and response to therapy carry more weight than stage alone. In DLBCL, marrow involvement is one factor in a broader risk assessment. In indolent lymphomas, it confirms advanced-stage disease, which influences whether treatment starts now or later. Your haemato-oncologist will explain what it means specifically for your situation.
I had a G-CSF injection before my PET. Could that affect the result?
Yes. G-CSF stimulates the bone marrow to produce white blood cells, which increases metabolic activity throughout the marrow and produces diffuse uptake on PET that can resemble lymphoma involvement. PET is usually timed to avoid this window. If yours was not, tell your haemato-oncologist — they may want to correlate the result with a biopsy or consider repeating the scan before drawing conclusions about marrow status.
My report says the marrow is not involved. Can I trust that?
In Hodgkin lymphoma and DLBCL, a PET scan showing no marrow involvement carries a high negative predictive value according to NCCN and ESMO — meaning it is reliable reassurance for staging. In indolent lymphomas, a negative PET is less conclusive, because these cancers often infiltrate the marrow in a way that is not FDG-avid. Your haemato-oncologist will tell you whether biopsy is still needed given your specific lymphoma type.
My PET and biopsy give different results. Which is right?
Both can be accurate and still appear to conflict — this is called discordant staging. The most common scenario in DLBCL is that biopsy finds a low-grade component in the marrow that did not take up the PET tracer strongly enough to appear on the scan. This discordant finding changes the stage and is clinically meaningful. Your haemato-oncologist will decide which finding drives the treatment plan — there is no single rule that applies to every patient.
Does stage IV from marrow involvement mean the lymphoma cannot be treated?
No. Stage IV in lymphoma is not synonymous with untreatable. In Hodgkin lymphoma, stage IV disease is still routinely approached with curative intent. In DLBCL, marrow involvement is one of several prognostic factors, and complete remission remains the goal. In indolent lymphomas, stage IV at diagnosis is very common and consistent with many years of well-managed disease. Stage tells your team where the disease is — it does not set a ceiling on what treatment can aim for.
Book a PET-CT at CION from Rs 10,499 — among the lowest published prices in Hyderabad — with an oncologist-reviewed report and a free Rs 950 consultation, across 4 partner centres. Indicative price, as of September 2026.
Explore 100 more PET-CT for Your Cancer Type topics
Lymphoma & Blood Cancer PET-CT
- Bone Marrow Involvement on PET in Lymphoma
- Deauville Score in Lymphoma: The Complete Guide
- End-of-Treatment PET in Lymphoma
- How Many PET Scans Will a Lymphoma Patient Need?
- Interim PET in Lymphoma: The Scan That Changes Treatment
- Lymphoma Staging on PET-CT: Ann Arbor and Lugano
- PET-CT Cost Across a Lymphoma Treatment Course
- PET-CT for Hodgkin vs Non-Hodgkin Lymphoma
- PET-CT for Lymphoma: Why It Matters More Here
- PET-CT for Multiple Myeloma
- PET-CT in Leukaemia: When Is It Used?
- Residual Mass After Lymphoma Treatment: Scar or Disease?
- Surveillance PET Scans After Lymphoma Remission
- Thymic Rebound and Marrow Uptake in Young Lymphoma Patients
Breast Cancer PET-CT
- Axillary Node Uptake on PET for Breast Cancer
- Bone Metastases in Breast Cancer: PET or Bone Scan?
- Breastfeeding and PET-CT Scans
- Incidental Breast Uptake Found on a Scan for Something Else
- Is a PET-CT Needed for Early Breast Cancer?
- PET-CT Cost for Breast Cancer Staging in Hyderabad
- PET-CT and Breast Implants
- PET-CT for Breast Cancer Recurrence
- PET-CT for Breast Cancer: When Is It Needed?
- PET-CT for Locally Advanced Breast Cancer
- PET-CT for Triple-Negative and HER2-Positive Breast Cancer
- PET-CT to Check Response in Breast Cancer
GI, Liver & Colorectal PET-CT
- Focal Bowel Uptake: When to Do a Colonoscopy
- Mucinous Tumours: Why PET Often Misses Them
- PET-CT Before Liver Resection or HIPEC
- PET-CT Cost for GI Cancer Staging in Hyderabad
- PET-CT for Colorectal Cancer
- PET-CT for Gallbladder and Bile Duct Cancer
- PET-CT for Liver Cancer (Hepatocellular Carcinoma)
- PET-CT for Liver Metastases: How Reliable?
- PET-CT for Oesophageal and Stomach Cancer
- PET-CT for Pancreatic Cancer
- Peritoneal Spread on PET-CT: What It Can and Cannot See
- Rising CEA With Normal Scans: Where Does PET Fit?
Gynaecological Cancer PET-CT
- PET-CT After Chemoradiation for Cervical Cancer
- PET-CT Cost for Gynaecological Cancer in Hyderabad
- PET-CT and Pregnancy: Why It Is Avoided
- PET-CT for Cervical Cancer
- PET-CT for Endometrial and Uterine Cancer
- PET-CT for Gestational Trophoblastic Disease
- PET-CT for Ovarian Cancer
- PET-CT for Vulvar and Vaginal Cancer
- Para-Aortic Node Uptake in Cervical Cancer
- Physiological Uterine and Ovarian Uptake
- Rising CA-125 With Normal Scans
- Why the Bladder Makes Pelvic PET Harder to Read
Head, Neck & Thyroid PET-CT
- Dental Work, Fillings and Artefacts on Head-Neck PET
- Neck Node Uptake on PET: What It Means
- PET-CT After Radiotherapy for Head and Neck Cancer
- PET-CT Cost for Head and Neck Cancer in Hyderabad
- PET-CT for Cancer of Unknown Primary in the Neck
- PET-CT for Head and Neck Cancer
- PET-CT for Nasopharyngeal Cancer
- PET-CT for Oral Cancer Staging
- PET-CT for Salivary Gland and Sinus Tumours
- PET-CT for Thyroid Cancer: When Is It Used?
- Rising Thyroglobulin With a Negative Iodine Scan
- Vocal Cord and Muscle Uptake in the Neck
Lung Cancer PET-CT
- Adrenal Findings During Lung Cancer Staging
- Brain Metastases: Why PET Is Not Enough for Lung Cancer
- Lung Nodule With High Uptake: Cancer or TB?
- Mediastinal Nodes on PET-CT: Staging the Chest
- PET-CT After Lung Cancer Treatment
- PET-CT Before Lung Cancer Surgery
- PET-CT Cost for Lung Cancer Staging in Hyderabad
- PET-CT for Lung Cancer: What It Shows
- PET-CT for Mesothelioma
- PET-CT for Small Cell Lung Cancer
- PET-CT for a Lung Nodule: Is It Cancer?
- Pleural Effusion and Pleural Uptake on PET
Non-Oncology PET-CT
- Brain PET for Dementia and Memory Loss
- Brain PET for Epilepsy and Seizure Focus
- Cardiac PET for Heart Muscle Viability
- Cardiac PET for Sarcoidosis and Inflammation
- Does a Non-Cancer PET-CT Cost the Same?
- PET-CT for Fever of Unknown Origin
- PET-CT for Non-Cancer Conditions: Why You Have Been Referred
- PET-CT for Suspected Bone or Spine Infection
- PET-CT for Suspected Infection in Implants and Grafts
- PET-CT for Unexplained Weight Loss
- PET-CT for Vasculitis and Large Vessel Inflammation
- Preparation for a Cardiac or Brain PET Scan
- What If a Non-Cancer PET Scan Finds Something Suspicious?
- Who Reports a Non-Oncology PET Scan?
Urological & Other Cancer PET-CT
- PET-CT Cost for Urological Cancers in Hyderabad
- PET-CT for Bladder Cancer
- PET-CT for Bone Metastases From Any Cancer
- PET-CT for Brain Tumours: Why MRI Comes First
- PET-CT for Kidney Cancer: Why FDG Is Unreliable
- PET-CT for Melanoma
- PET-CT for Neuroendocrine Tumours: FDG or DOTA?
- PET-CT for Paediatric Cancers
- PET-CT for Rare and Unusual Cancers
- PET-CT for Sarcoma
- PET-CT for Skin and Merkel Cell Cancers
- PET-CT for Testicular Cancer
Your next step
Talk to an oncologist about your scan
Your PET-CT report read by a senior oncologist, explained in plain language, with a free 45-minute consultation.
Common questions
Frequently asked questions
Can a PET scan replace bone marrow biopsy in lymphoma?
For Hodgkin lymphoma and diffuse large B-cell lymphoma, yes — NCCN and ESMO guidelines accept PET-CT as sufficient to stage marrow involvement, so routine biopsy is not required in most cases. For indolent lymphomas such as follicular or marginal zone lymphoma, biopsy remains more reliable, because these cancers often infiltrate the marrow in a way PET does not detect. Whether biopsy is needed depends on your lymphoma type, which your haemato-oncologist will clarify.
What does diffuse bone marrow uptake mean on a PET scan?
Diffuse uptake means a broad, even increase in metabolic activity across multiple bones rather than a focal hotspot. This pattern is less specific for lymphoma — it also appears after infection, anaemia, and G-CSF use. Your haemato-oncologist will interpret it alongside your clinical history and the timing of the scan before drawing any conclusion about whether it represents true lymphoma involvement.
What does focal bone marrow uptake mean on a PET scan?
Focal uptake means a discrete, localised area of increased activity at a specific site within the bone or marrow. This is more specific for lymphoma involvement than diffuse uptake, and it is what staging systems use when classifying marrow as positive. A focal finding changes the stage and will be discussed with you by your haemato-oncologist as part of your full staging assessment.
Does bone marrow involvement mean the lymphoma has spread too far to treat?
No. Marrow involvement places the lymphoma at stage IV under the Lugano classification, but stage IV does not mean untreatable. In Hodgkin lymphoma, stage IV is still approached with curative intent. In DLBCL, marrow involvement is one factor in a broader risk assessment. In indolent lymphomas, stage IV at diagnosis is common and consistent with many years of managed disease. What it means for your situation is a direct conversation to have with your haemato-oncologist.
Why would a biopsy find lymphoma in the marrow when PET did not?
This is discordant marrow involvement. It typically occurs in DLBCL, where the marrow can contain a different, lower-grade cell type that does not take up the PET tracer — invisible on scan but detectable by biopsy. This finding changes the stage and is clinically meaningful. Your haemato-oncologist will tell you whether this possibility is relevant to your case and how it affects the treatment plan.
What should I ask at my next appointment about the marrow findings?
Ask three things: what the marrow finding specifically is — diffuse, focal, or negative — and what it means for your lymphoma type; whether a biopsy is needed and why; and how the result changes your stage and what that means for the treatment being recommended. These are direct questions your haemato-oncologist should answer specifically. Asking for the key points in writing helps, because these conversations are hard to retain afterwards.